Patents by Inventor Marion Ohlmann
Marion Ohlmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8197825Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: GrantFiled: June 14, 2010Date of Patent: June 12, 2012Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Patent number: 8153138Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: GrantFiled: September 19, 2006Date of Patent: April 10, 2012Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Publication number: 20100291139Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: ApplicationFiled: June 14, 2010Publication date: November 18, 2010Inventors: GERD SUTTER, Marion Ohlmann, Volker Erfle
-
Publication number: 20100266630Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: ApplicationFiled: September 19, 2006Publication date: October 21, 2010Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Publication number: 20090226415Abstract: The invention relates to modified tridegins, polypeptides derived from SEQ ID No. 1, in which the modification is replacement of a cysteine residue and/or one of the following amino acids—Lys2, Lys7, His10, Gly12, Leu24, Tyr31, Phe34, Arg39, Ile45, Met48, Asp50, Pro55, Phe58, Asn60, Pro65, Arg66, by another amino acid and/or N- or C-terminal deletion, whereby the remaining polypeptide comprises at least the amino acid sequence DDIYQRXVXFPXLPL (SEQ ID NO.89) and/or a covalent bonding to polyethylene glycol. Said polypeptides are novel inhibitors of transglutaminases, in particular of Factor XIIIa, of the terminal enzymes in the blood coagulation cascade. The invention further relates to methods for production of said inhibitors and the use thereof as transglutaminase inhibitors.Type: ApplicationFiled: March 18, 2009Publication date: September 10, 2009Inventors: Helmut Giersiefen, Johannes Stoeckel, Tanja Pamp, Marion Ohlmann
-
Patent number: 7198934Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: GrantFiled: May 15, 2002Date of Patent: April 3, 2007Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Publication number: 20070071770Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: ApplicationFiled: September 19, 2006Publication date: March 29, 2007Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Publication number: 20070071769Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: ApplicationFiled: September 19, 2006Publication date: March 29, 2007Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Patent number: 7150874Abstract: A new DNA vector is disclosed comprising a nucleic acid sequence useful for inserting heterologous sequences into the genome of poxviruses by homologous recombination. Also disclosed are recombinant poxviruses carrying heterologous coding sequences transferred by the DNA vector.Type: GrantFiled: September 23, 2003Date of Patent: December 19, 2006Assignee: GFS Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Stefan Wintersperger, Robert Baier, Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Publication number: 20060246046Abstract: The invention relates to modified tridegins, polypeptides derived from SEQ ID No. 1, in which the modification is replacement of a cysteine residue and/or one of the following amino acids—Lys2, Lys7, His10, Gly12, Leu24, Tyr31, Phe34, Arg39, Ile45, Met48, Asp50, Pro55, Phe58, Asn60, Pro65, Arg66, by another amino acid and/or N- or C-terminal deletion, whereby the remaining polypeptide comprises at least the amino acid sequence DDIYQRXVXFPXLPL (SEQ ID NO.89) and/or a covalent bonding to polyethylene glycol. Said polypeptides are novel inhibitors of transglutaminases, in particular of Factor XIIIa, of the terminal enzymes in the blood coagulation cascade. The invention further relates to methods for production of said inhibitors and the use thereof as transglutaminase inhibitors.Type: ApplicationFiled: December 20, 2002Publication date: November 2, 2006Inventors: Helmut Giersiefen, Johannes Stockel, Tanja Pamp, Marion Ohlmann
-
Publication number: 20040228840Abstract: A new DNA vector is disclosed comprising a nucleic acid sequence useful for inserting heterologous sequences into the genome of poxviruses by homologous recombination. Also disclosed are recombinant poxviruses carrying heterologous coding sequences transferred by the DNA vector.Type: ApplicationFiled: September 23, 2003Publication date: November 18, 2004Applicant: GSF FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GMBHInventors: Stefan Wintersperger, Robert Baier, Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Patent number: 6682742Abstract: The present invention provides a DNA vector comprising a nucleic acid sequence useful for inserting heterologous sequences into the genome of poxviruses by homologous recombination. The present invention relates also, inter alia, to recombinant poxvirses carrying heterologous coding sequences transferred by the vector according to the present invention.Type: GrantFiled: December 26, 2001Date of Patent: January 27, 2004Assignee: GSF Forschungszentrum fur Unwelt und Gesundheit GmbHInventors: Stefan Wintersperger, Robert Baier, Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Publication number: 20030035792Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: ApplicationFiled: May 15, 2002Publication date: February 20, 2003Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Patent number: 6440422Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: GrantFiled: January 2, 1998Date of Patent: August 27, 2002Assignee: GSF-Forschungszentrum fur Umwelt und Gesenudheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle